These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 29441052)

  • 21. Ursolic Acid Promotes Autophagy by Inhibiting Akt/mTOR and TNF-α/TNFR1 Signaling Pathways to Alleviate Pyroptosis and Necroptosis in Mycobacterium tuberculosis-Infected Macrophages.
    Shen J; Fu Y; Liu F; Ning B; Jiang X
    Inflammation; 2023 Oct; 46(5):1749-1763. PubMed ID: 37212951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?
    Park HE; Lee W; Shin MK; Shin SJ
    Front Immunol; 2021; 12():703060. PubMed ID: 34262571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis.
    Tasneen R; Mortensen DS; Converse PJ; Urbanowski ME; Upton A; Fotouhi N; Nuermberger E; Hawryluk N
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0025321. PubMed ID: 33903099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New insights into the evasion of host innate immunity by Mycobacterium tuberculosis.
    Chai Q; Wang L; Liu CH; Ge B
    Cell Mol Immunol; 2020 Sep; 17(9):901-913. PubMed ID: 32728204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.
    Hawn TR; Shah JA; Kalman D
    Immunol Rev; 2015 Mar; 264(1):344-62. PubMed ID: 25703571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of differential identification of Mycobacterium tuberculosis strains for understanding differences in their prevalence, treatment efficacy, and vaccine development.
    Chae H; Shin SJ
    J Microbiol; 2018 May; 56(5):300-311. PubMed ID: 29721826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein Kinase R Restricts the Intracellular Survival of
    Smyth R; Berton S; Rajabalee N; Chan T; Sun J
    Front Microbiol; 2020; 11():613963. PubMed ID: 33552025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Macrophage Response to
    Maphasa RE; Meyer M; Dube A
    Front Cell Infect Microbiol; 2020; 10():618414. PubMed ID: 33628745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk Factors for Multidrug-resistant Tuberculosis.
    Rumende CM
    Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harnessing host-pathogen interactions for innovative drug discovery and host-directed therapeutics to tackle tuberculosis.
    Saini S; Gangwar A; Sharma R
    Microbiol Res; 2023 Oct; 275():127466. PubMed ID: 37531813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell death at the cross roads of host-pathogen interaction in Mycobacterium tuberculosis infection.
    Mohareer K; Asalla S; Banerjee S
    Tuberculosis (Edinb); 2018 Dec; 113():99-121. PubMed ID: 30514519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunometabolism of Phagocytes During
    Kumar R; Singh P; Kolloli A; Shi L; Bushkin Y; Tyagi S; Subbian S
    Front Mol Biosci; 2019; 6():105. PubMed ID: 31681793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bazedoxifene Suppresses Intracellular Mycobacterium tuberculosis Growth by Enhancing Autophagy.
    Ouyang Q; Zhang K; Lin D; Feng CG; Cai Y; Chen X
    mSphere; 2020 Apr; 5(2):. PubMed ID: 32269154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miRNAs in Tuberculosis: New Avenues for Diagnosis and Host-Directed Therapy.
    Sabir N; Hussain T; Shah SZA; Peramo A; Zhao D; Zhou X
    Front Microbiol; 2018; 9():602. PubMed ID: 29651283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of Cystatin F in Human Macrophages Impacts Cathepsin-Driven Killing of Multidrug-Resistant
    Mandal M; Pires D; Catalão MJ; Azevedo-Pereira JM; Anes E
    Microorganisms; 2023 Jul; 11(7):. PubMed ID: 37513033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opportunities and Challenges for Host-Directed Therapies in Tuberculosis.
    Sachan M; Srivastava A; Ranjan R; Gupta A; Pandya S; Misra A
    Curr Pharm Des; 2016; 22(17):2599-604. PubMed ID: 26818871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Everolimus Activity against
    Bianco DM; De Maio F; Santarelli G; Palucci I; Salustri A; Bianchetti G; Maulucci G; Citterio F; Sanguinetti M; Tamburrini E; Sali M; Delogu G
    Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.